Topic Highlight
Copyright ©2010 Baishideng. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2010; 2(2): 98-101
Published online Feb 15, 2010. doi: 10.4251/wjgo.v2.i2.98
Peritoneal carcinomatosis of colorectal origin
Antonio Macrì, Edoardo Saladino, Vincenzo Bartolo, Vincenzo Adamo, Giuseppe Altavilla, Epifanio Mondello, Giovanni Condemi, Angelo Sinardi, Ciro Famulari
Antonio Macrì, Edoardo Saladino, Vincenzo Bartolo, Ciro Famulari, University of Messina, Department of Human Pathology, General Surgery Unit, 98125 Messina, Italy
Vincenzo Adamo, Giuseppe Altavilla, University of Messina, Department of Human Pathology, Medical Oncology Unit, 98125 Messina, Italy
Epifanio Mondello, Angelo Sinardi, University of Messina, Anesthesiology Unit, 98125 Messina, Italy
Giovanni Condemi, Ospedali Riuniti della Locride, Hospital of Siderno, Medical Oncology Unit, 89048 Siderno, Italy
Author contributions: Macrì A, Saladino E and Famulari C performed research; Macrì A, Saladino E, Bartolo V, Adamo V, Altavilla G, Mondello E, Condemi G, Sinardi A, and Famulari C analyzed the data; Macrì A, Saladino E and Famulari C wrote the paper.
Correspondence to: Antonio Macrì, MD, Professor, University of Messina, Department of Human Pathology, General Surgery Unit, Via Consolare Valeria, 98125 Messina, Italy. amacri@unime.it
Telephone: +39-90-2212678 Fax: +39-90-2212683
Received: July 31, 2009
Revised: October 8, 2009
Accepted: October 15, 2009
Published online: February 15, 2010
Abstract

Peritoneal carcinomatosis is, after liver metastases, the second most frequent cause of death in colorectal cancer patients and at the present time, is commonly inserted and treated as a stage IV tumour. Because there is no published data that outlines the impact of new therapeutic regimens on survival of patients with peritoneal surface diffusion, the story of carcinomatosis can be rewritten in light of a new aggressive approach based on the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Also if these treatment perhaps allow to obtain better results than standard therapies, we suggest, that a large prospective randomised control trial is needed to compare long-term and progression-free survival under the best available systemic therapy with or without cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Keywords: Colorectal cancer, Peritoneal carcinomatosis, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy